Table 1.
Characteristics of studies included in meta-analysis
| Reference numbers | First author | Type of study | Location | Sample size | Morbidities (HAS/DM/DCV/ACE OU BRA) | Outcome (severity and/or mortality) |
|---|---|---|---|---|---|---|
| [14] | Li et al. | Case Series | CHINA | 362 | HAS/DM/DCV/ACEI/ARB uses | Severity and Mortality |
| [15] | Giamarellos-Bourboulis et al. | Case Series | GREECE | 54 | DM/DCV | Severity |
| [16] | Zhang et al. | Retrospective Cohort | CHINA | 19 | HAS/DM/DCV | Mortality |
| [17] | Zhou et al. | Retrospective Cohort | CHINA | 191 | HAS/DM/DCV | Mortality |
| [18] | Colombi et al. | Retrospective Cohort | ITALY | 236 | DM/DCV | Severity |
| [19] | Li et al. | Cross Sectional | CHINA | 548 | HAS/DM/DCV/ACEI/ARB use | Severity |
| [20] | Lei et al. | Retrospective Cohort | CHINA | 34 | DM/DCV | Severity |
| [21] | Deng et al. | Retrospective Cohort | CHINA | 112 | HAS/DM/DCV | Severity |
| [22] | Guo et al. | Case Series | CHINA | 187 | HAS/DM/DCV/ACEI/ARB use | Severity |
| [23] | Huang et al. | Retrospective Cohort | CHINA | 41 | HAS/DM/DCV | Severity |
| [24] | Zhang et al. | Case Series | CHINA | 140 | HAS/DM/DCV | Severity |
| [25] | Liu et al. | Retrospective Cohort | CHINA | 78 | HAS/DM/DCV | Severity |
| [26] | Wang et al. | Retrospective Cohort | CHINA | 138 | HAS/DM/DCV | Severity |
| [27] | Guan et al. | Retrospective Cohort | CHINA | 1099 | HAS/DM/DCV | Severity and Mortality |
| [28] | Wu et al. | Retrospective Cohort | CHINA | 84 | HAS/DM/DCV | Mortality |
| [29] | Zhang et al. | Retrospective Cohort | CHINA | 221 | HAS/DM/DCV | Severity |
| [30] | Chen et al. | Retrospective Cohort | CHINA | 274 | HAS/DM/DCV | Mortality |
| [31] | Deng et al. | Retrospective Cohort | CHINA | 225 | HAS/DM/DCV | Mortality |
| [32] | Wang et al. | Case Series | CHINA | 69 | HAS/DM/DCV | Severity |
| [33] | Yang et al. | Retrospective Cohort | CHINA | 52 | DM/DCV | Mortality |
| [34] | Guan et al. | Case Series | CHINA | 1590 | DM/DCV | Mortality |
| [35] | Zheng et al. | Retrospective Cohort | CHINA | 161 | HAS/DM/DCV | Severity |
| [36] | Fan et al. | Retrospective Cohort | CHINA | 21 | HAS/DM/DCV | Mortality |
| [37] | Yuan et al. | Case Series | CHINA | 27 | HAS/DM/DCV | Severity |
| [38] | Feng et al. | Retrospective Cohort | CHINA | 476 | HAS/DM/DCV | Severity |
| [39] | Mao et al. | Case Series | CHINA | 214 | HAS/DM/DCV | Severity |
| [40] | Wang et al. | Retrospective Cohort | CHINA | 339 | HAS/DM/DCV | Mortality |
| [41] | Simonet et al. | Retrospective Cohort | FRANCE | 124 | HAS/DM/DCV | Severity |
| [42] | Chen et al. | Cross Sectional | CHINA | 150 | HAS | Severity |
| [43] | Wu et al. | Retrospective Cohort | CHINA | 201 | HAS | Severity |
| [44] | Xiang et al. | Cross Sectional | CHINA | 49 | HAS | Severity |
| [45] | Wan et al. | Cross Sectional | CHINA | 135 | HAS/DM/DCV | Severity |
| [46] | Qin et al. | Retrospective Cohort | CHINA | 452 | HAS | Severity |
| [47] | Ruan et al. | Retrospective Cohort | CHINA | 150 | HAS | Mortality |
| [48] | Zhang et al. | Retrospective Cohort | CHINA | 1128 | ACEI/ARB use | Mortality |
| [49] | Xu et al. | Retrospective Cohort | CHINA | 187 | HAS | Mortality |
| [50] | Meng et al. | Case series | CHINA | 42 | ACEI/ARB use | Severity |
| [51] | Yang et al. | Retrospective Cohort | CHINA | 125 | ACEI/ARB use | Severity |
| [52] | Mancia et al. | Retrospective Cohort | ITALY | 6272 | ACEI/ARB use | Severity |
| [53] | Reynolds et al. | Retrospective Cohort | USA | 2005 | ACEI/ARB use | Severity |
DM, diabetes mellitus; HAS, hypertension; DCV, cardiovascular disease; ACEI/ARB, angiotensin converting enzyme inhibitors/angiotensin II receptor blockers